AN2 Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANTX research report →
About the company
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
- CEO
- Eric E. Easom
- IPO
- 2022
- Employees
- 22
- HQ
- Menlo Park, CA, US
Price Chart
- Market Cap
- $121.12M
- P/E
- -4.36
- P/S
- 0.00
- P/B
- 1.84
- EV/EBITDA
- -1.89
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.35%
- ROIC
- -45.31%
- Revenue
- $0 · 0.00%
- Net Income
- $-35,174,000 · 31.46%
- EPS
- $-1.16 · 32.56%
- Op Income
- $-38,109,000
- FCF YoY
- 39.43%
- 52W High
- $6.91
- 52W Low
- $1.00
- 50D MA
- $4.59
- 200D MA
- $2.45
- Beta
- -0.98
- Avg Volume
- 328.03K
Get TickerSpark's AI analysis on ANTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 26 | Williams Sarah Joanne | sell | 265 |
| Apr 10, 26 | Aziz Kabeer | other | 3,775 |
| Apr 10, 26 | Marks Gilbert Lynn | other | 3,775 |
| Apr 10, 26 | Martin Patricia A. | other | 1,192 |
| Mar 19, 26 | Day Lucy | other | 82,300 |
| Mar 19, 26 | Day Lucy | other | 73,665 |
| Mar 19, 26 | Day Lucy | other | 66,000 |
| Mar 19, 26 | Day Lucy | sell | 82,300 |
| Mar 19, 26 | Day Lucy | sell | 73,665 |
| Mar 19, 26 | Day Lucy | sell | 66,000 |
Our ANTX coverage
Recent articles, reports, and earnings notes.
No research on ANTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANTX report →Similar companies
Peers in the same neighborhood.